PharmaTelevision - Molmed: Holger Neecke. How their TK cell-based therapy could offer a potential solution to patients unable to find a fully matched bone marrow donor

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Molmed: Holger Neecke. How their TK cell-based therapy could offer a potential solution to patients unable to find a fully matched bone marrow donor

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to Holger Neecke, Director Business Development & Investor Relations of Molmed.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

MolMed's areas of specialisation and strengths

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here at BIO-Europe, in Duesseldorf Germany in 2011. On this show I have Holger Neecke, who is the Director of Business Development & Investor Relations at an Italian company called MolMed, which is based in Milan and it's also listed on the Milan's Stock Exchange, welcome.

Holger Neecke:

Yes thank you for this opportunity.

Fintan Walton:

So Holger, could you tell us a little bit about the origins of MolMed?

Holger Neecke:

Yes, MolMed was founded in 1996 as a cell therapy company basic cell therapy services to do the closely associated hospital the San Raffaele hospital.

Fintan Walton:

Okay, so it was founded as a specialized science based company, what was its strength? What was it actual doing?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Holger Neecke

Director

At the time of this PTV interview Holger Neecke serves as Director Business Development & Investor Relations of MolMed. Holger Neecke joined MolMed in October 2001. Before, he worked at Biopolo Scrl, one of the leading biotechnology transfer agencies in Italy, where he developed and evaluated business plans for start-up companies. At MolMed, he has acquired a broad expertise in biotech business development, particularly by structuring, negotiating and finalizing important license agreements with pharma and biotech companies and institutions in Europe, Japan and the U.S. Holger Neecke holds a degree in Molecular Biology from the University of Basel, Switzerland, a PhD in Genetics from the University of Milan, and a MBA from SDA Bocconi Business School, Milan.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

MolMed

MolMed is a medical biotechnology company focused on discovery, R&D, and clinical validation of innovative therapies for the treatment of cancer. MolMed's approach to cancer is based on an integrated strategy that provides both drugs effectively targeting the growing tumormass in the acute stage, and highly selective therapies to eliminate residual disease. Since year 2000, MolMed has evolved into a biotechnology drug-developing company, with a primary focus on novel cancer therapies. Today, MolMed is a mature company covering all functions, from discovery to proof of clinical activity. MolMed is located in Milan, Italy, within the San Raffaele Biomedical Science Park, which includes the renowned research hospital and scientific institute, along with several thriving biotechnology companies, and a private university. This location offers crucial advantages, allowing MolMed to complement its own R&D resources with the cutting-edge technological and clinical resources of its host institution, also because of its option right on research results of the Scientific Institute. The San Raffaele Scientific Institute counts over 500 scientists, and the hospital is the largest Italian private clinical centre, with over 1400 beds and more than 100 clinical studies running each year.